Zoetis Inc. (NYSE:ZTS) Shares Bought by Baldwin Wealth Partners LLC MA

Baldwin Wealth Partners LLC MA lifted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 5.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 74,961 shares of the company’s stock after acquiring an additional 4,002 shares during the period. Baldwin Wealth Partners LLC MA’s holdings in Zoetis were worth $12,213,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ZTS. Kavar Capital Partners Group LLC raised its position in shares of Zoetis by 86.8% in the fourth quarter. Kavar Capital Partners Group LLC now owns 10,268 shares of the company’s stock valued at $1,673,000 after buying an additional 4,772 shares during the last quarter. Pacer Advisors Inc. grew its stake in Zoetis by 12.4% in the 4th quarter. Pacer Advisors Inc. now owns 52,401 shares of the company’s stock worth $8,538,000 after acquiring an additional 5,790 shares during the period. Union Bancaire Privee UBP SA purchased a new position in shares of Zoetis during the 4th quarter worth $898,000. Blue Trust Inc. boosted its holdings in shares of Zoetis by 85.1% during the fourth quarter. Blue Trust Inc. now owns 9,353 shares of the company’s stock worth $1,524,000 after purchasing an additional 4,301 shares during the last quarter. Finally, PFG Investments LLC grew its position in shares of Zoetis by 3.7% in the fourth quarter. PFG Investments LLC now owns 3,265 shares of the company’s stock valued at $532,000 after purchasing an additional 115 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

ZTS stock opened at $171.32 on Monday. The firm has a market cap of $77.30 billion, a P/E ratio of 32.16, a price-to-earnings-growth ratio of 2.57 and a beta of 0.89. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. Zoetis Inc. has a 1 year low of $144.80 and a 1 year high of $200.53. The stock has a 50-day simple moving average of $170.10 and a 200-day simple moving average of $179.75.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Monday, November 4th. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. During the same quarter last year, the company earned $1.36 earnings per share. Zoetis’s revenue for the quarter was up 11.6% on a year-over-year basis. On average, equities analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, January 21st will be issued a $0.50 dividend. The ex-dividend date of this dividend is Tuesday, January 21st. This represents a $2.00 dividend on an annualized basis and a yield of 1.17%. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s payout ratio is currently 37.59%.

Analysts Set New Price Targets

A number of analysts have issued reports on ZTS shares. Stifel Nicolaus lowered their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. UBS Group began coverage on shares of Zoetis in a report on Monday, December 9th. They issued a “neutral” rating and a $196.00 target price for the company. Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. JPMorgan Chase & Co. boosted their price objective on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Finally, Leerink Partners initiated coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. One equities research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.